Artelo Biosciences (ARTL) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
14 May, 2026Management team and governance
Principal executive officers include the President/CEO, CFO, and several directors, all of whom have signed the registration statement as of May 14, 2026.
The company is incorporated in Nevada and operates from Solana Beach, CA.
Indemnification agreements are in place for directors and officers, providing maximum protection allowed by Nevada law, and the company maintains insurance for these individuals.
Offering details and pricing
The registration statement is filed on Form S-3, allowing for the offer and sale of securities from time to time after effectiveness.
The offering may include various types of securities, including debt securities, as detailed in the filed Indenture.
Estimated SEC registration fee is $788.05, with additional fees for accounting, legal, and other services to be determined based on the size and type of offering.
Unsold securities from a previous registration statement will have their registration fees carried forward.
Underwriters and syndicate
The form of underwriting agreement is listed as an exhibit, to be filed by amendment or incorporated by reference.
Latest events from Artelo Biosciences
- Q1 2026 net loss reached $3.0M; cash at $10.3M after $10M financing, but going concern risk remains.ARTL
Q1 202615 May 2026 - Advancing novel lipid signaling drugs with strong clinical data and large market potential.ARTL
Corporate presentation14 May 2026 - Shareholders will vote on director elections, executive pay, enhanced governance, and updated executive agreements.ARTL
Proxy filing6 May 2026 - Biopharma aims to raise up to $75M for novel therapies in oncology and neurology via shelf offering.ARTL
Registration filing4 May 2026 - Biopharma registers 9.8M shares for resale, targeting unmet needs but facing dilution risks.ARTL
Registration filing7 Apr 2026 - Equity line agreement enables up to $50M in funding but poses dilution and market risks.ARTL
Registration filing24 Mar 2026 - Biopharma seeks $10.9M via equity/warrants to fund clinical pipeline amid Nasdaq compliance risks.ARTL
Registration filing24 Mar 2026 - Lead programs show strong clinical progress in cancer anorexia, neuropathy, and anxiety.ARTL
Corporate presentation24 Mar 2026 - Biopharma seeks up to $10.8M via share/warrant offering to fund clinical pipeline, with dilution risk.ARTL
Registration filing23 Mar 2026